Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, …, Motzer RJ · 2007 · New England Journal of Medicine · Atlas ID HUD2007

What this study shows

Temsirolimus alone extended median overall survival to 10.9 months versus 7.3 months with interferon alfa in poor-prognosis metastatic kidney cancer; rash, hyperglycemia, and hyperlipidemia were more common with temsirolimus.

Abstract

ShowHide

Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	2 - Human Clinical Trial
Model system	Humans, phase III RCT (n=626)
Journal	New England Journal of Medicine
Year	2007
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1056/NEJMoa066838 · PMID 17538086

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Temsirolimus (± interferon alfa)
Target	mTOR
Model	Human – phase III RCT (n=626, poor-prognosis RCC)
Effect	Temsirolimus improved overall survival vs interferon alfa in poor-prognosis metastatic renal-cell carcinoma

In the Atlas

Links in the pathway map

Supports mTORC1 is associated with Renal cell carcinoma (RCC)
Supports Temsirolimus inhibits mTORC1
Supports Temsirolimus inhibits Renal cell carcinoma (RCC)

Answers that reference this study

Discussed in the plain-language answer How does mTOR connect to cancer?.
Discussed in the plain-language answer What are mTOR inhibitors? The full list, by mechanism.

Cite this paper

ShowHide

Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., Kovacevic, Z., Lesovoy, V., Schmidt-Wolf, I. G., Barbarash, O., Gokmen, E., O'Toole, T., Lustgarten, S., Moore, L., & Motzer, R. J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa066838

@article{HUD2007,
  author       = {Hudes, G. and Carducci, M. and Tomczak, P. and Dutcher, J. and Figlin, R. and Kapoor, A. and Staroslawska, E. and Sosman, J. and McDermott, D. and Bodrogi, I. and Kovacevic, Z. and Lesovoy, V. and Schmidt-Wolf, I. G. and Barbarash, O. and Gokmen, E. and O'Toole, T. and Lustgarten, S. and Moore, L. and Motzer, R. J.},
  title        = {{Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma}},
  journal      = {New England Journal of Medicine},
  year         = {2007},
  doi          = {10.1056/NEJMoa066838},
  note         = {PMID: 17538086},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record HUD2007) [Data set]. https://mtor-atlas.org/study/HUD2007/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_HUD2007,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record HUD2007},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/HUD2007/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?